These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 15533263)
1. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Cani PD; Montoya ML; Neyrinck AM; Delzenne NM; Lambert DM Br J Nutr; 2004 Nov; 92(5):757-61. PubMed ID: 15533263 [TBL] [Abstract][Full Text] [Related]
2. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. Gómez R; Navarro M; Ferrer B; Trigo JM; Bilbao A; Del Arco I; Cippitelli A; Nava F; Piomelli D; Rodríguez de Fonseca F J Neurosci; 2002 Nov; 22(21):9612-7. PubMed ID: 12417686 [TBL] [Abstract][Full Text] [Related]
3. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748 [TBL] [Abstract][Full Text] [Related]
4. Effects of combined oleoyl-estrone and rimonabant on overweight rats. Ferrer-Lorente R; Cabot C; Fernández-López JA; Alemany M J Pharmacol Sci; 2007 Jun; 104(2):176-82. PubMed ID: 17558182 [TBL] [Abstract][Full Text] [Related]
6. Ghrelin-induced orexigenic effect in rats depends on the metabolic status and is counteracted by peripheral CB1 receptor antagonism. Alen F; Crespo I; Ramírez-López MT; Jagerovic N; Goya P; de Fonseca FR; de Heras RG; Orio L PLoS One; 2013; 8(4):e60918. PubMed ID: 23565287 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors. Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266 [TBL] [Abstract][Full Text] [Related]
9. Attenuation of oleoylethanolamide-induced reduction of alcohol consumption in adult rats exposed intermittently to alcohol during adolescence. Sánchez-Marín L; Pavón-Morón FJ; Rodríguez de Fonseca F; Serrano A Neurosci Lett; 2022 Jun; 781():136670. PubMed ID: 35500667 [TBL] [Abstract][Full Text] [Related]
10. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Verty AN; McGregor IS; Mallet PE Neurosci Lett; 2004 Jan; 354(3):217-20. PubMed ID: 14700735 [TBL] [Abstract][Full Text] [Related]
11. Role of oleoylethanolamide as a feeding regulator in goldfish. Tinoco AB; Armirotti A; Isorna E; Delgado MJ; Piomelli D; de Pedro N J Exp Biol; 2014 Aug; 217(Pt 15):2761-9. PubMed ID: 24855680 [TBL] [Abstract][Full Text] [Related]
12. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428 [TBL] [Abstract][Full Text] [Related]
13. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510 [TBL] [Abstract][Full Text] [Related]
14. Impact of inulin and oligofructose on gastrointestinal peptides. Delzenne NM; Cani PD; Daubioul C; Neyrinck AM Br J Nutr; 2005 Apr; 93 Suppl 1():S157-61. PubMed ID: 15877889 [TBL] [Abstract][Full Text] [Related]
15. Oleoylethanolamide: effects on hypothalamic transmitters and gut peptides regulating food intake. Serrano A; Pavón FJ; Tovar S; Casanueva F; Señarís R; Diéguez C; de Fonseca FR Neuropharmacology; 2011 Mar; 60(4):593-601. PubMed ID: 21172362 [TBL] [Abstract][Full Text] [Related]
16. Oleoylethanolamide: a novel potential pharmacological alternative to cannabinoid antagonists for the control of appetite. Romano A; Coccurello R; Giacovazzo G; Bedse G; Moles A; Gaetani S Biomed Res Int; 2014; 2014():203425. PubMed ID: 24800213 [TBL] [Abstract][Full Text] [Related]
17. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21. Pavon FJ; Bilbao A; Hernández-Folgado L; Cippitelli A; Jagerovic N; Abellán G; Rodríguez-Franco MA; Serrano A; Macias M; Gómez R; Navarro M; Goya P; Rodríguez de Fonseca F Neuropharmacology; 2006 Aug; 51(2):358-66. PubMed ID: 16750544 [TBL] [Abstract][Full Text] [Related]
18. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Tucci SA; Rogers EK; Korbonits M; Kirkham TC Br J Pharmacol; 2004 Nov; 143(5):520-3. PubMed ID: 15381634 [TBL] [Abstract][Full Text] [Related]
19. Cannabinoid CB(1) receptor blockade enhances the protective effect of melanocortins in hemorrhagic shock in the rat. Cainazzo MM; Ferrazza G; Mioni C; Bazzani C; Bertolini A; Guarini S Eur J Pharmacol; 2002 Apr; 441(1-2):91-7. PubMed ID: 12007925 [TBL] [Abstract][Full Text] [Related]
20. SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Costa B; Colleoni M Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1103-8. PubMed ID: 11189200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]